Drug Trial Radar · NCT04995523
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
212
Actual
Start
Sep 14, 2021
Primary completion
Jun 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Conditions
- Non-Small-Cell Lung Carcinoma
Interventions
AZD2936Drug
Anti-TIGIT/Anti-PD-1 Bispecific Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parametersTime frame: Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
- Rate of rilvegostomig discontinuation due to toxicityTime frame: Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
- Objective Response Rate (ORR)Time frame: Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)
Locations
40 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Chicago, Illinois
Research Site
Rochester, Minnesota
Research Site
Fairfax, Virginia
Research Site
Melbourne, Australia
Research Site
Anderlecht, Belgium
Research Site
Leuven, Belgium
Research Site
Florianópolis, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Copenhagen, Denmark
Research Site
Dijon, France
Research Site
Toulouse, France
Research Site
Tbilisi, Georgia
Research Site
Kashiwa, Japan
Research Site
Niigata, Japan
Research Site
Sendai, Japan
Research Site
Tokyo, Japan
Research Site
Kuala Lumpur, Malaysia
Research Site
Kuching, Malaysia
Research Site
Chisinau, Moldova
Research Site
Groningen, Netherlands
Research Site
Leiden, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Taichung, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Bangkok, Thailand
Research Site
Chanthaburi, Thailand
Research Site
Muang, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.